Neurocognitive Disorder Due to Alzheimer's Disease: Symptoms, Diagnosis, and Treatment

Neurocognitive Disorder Due to Alzheimer's Disease is the clinical term used in the DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision) for the progressive cognitive decline caused by Alzheimer's disease pathology. It is the most common cause of neurocognitive disorder — what was historically called "dementia" — accounting for an estimated 60–80% of all dementia cases.

The DSM-5-TR classifies this condition into two levels of severity:

• Mild Neurocognitive Disorder Due to Alzheimer's Disease — sometimes informally called "mild cognitive impairment (MCI) due to Alzheimer's." At this stage, a person experiences modest cognitive decline that does not significantly interfere with independence in daily activities, though tasks may require more effort, compensatory strategies, or accommodation.
• Major Neurocognitive Disorder Due to Alzheimer's Disease — this corresponds to what most people recognize as Alzheimer's dementia. Cognitive decline is substantial enough to interfere with independence, and the person typically requires assistance with instrumental or basic activities of daily living.

Alzheimer's disease is a neurodegenerative condition, meaning it involves the progressive loss of neurons and brain tissue. At the neuropathological level, it is defined by the accumulation of amyloid-beta plaques (abnormal protein deposits between neurons) and neurofibrillary tangles (twisted strands of tau protein inside neurons). These changes typically begin in the hippocampus and entorhinal cortex — brain regions critical for memory formation — and gradually spread to other cortical areas.

According to the Alzheimer's Association, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer's dementia in 2023. The World Health Organization (WHO) estimates that over 55 million people worldwide live with dementia, with Alzheimer's disease as the leading cause. The condition is age-related: prevalence roughly doubles every five years after age 65, affecting approximately 5% of those aged 65–74, 13% of those aged 75–84, and over 33% of those aged 85 and older.

Alzheimer's disease typically has an insidious onset — meaning it begins gradually, often so subtly that the earliest changes are difficult to distinguish from normal age-related cognitive shifts. The hallmark feature is progressive memory impairment, particularly difficulty forming new memories (anterograde amnesia). However, Alzheimer's disease affects multiple cognitive domains over time.

Early warning signs include:

• Memory lapses that disrupt daily life — repeatedly asking the same questions, forgetting recently learned information, increasingly relying on memory aids or family members for things one used to handle independently
• Difficulty with planning and problem-solving — trouble following a familiar recipe, managing finances, or keeping track of monthly bills
• Challenges completing familiar tasks — difficulty driving to a well-known location, remembering rules of a favorite game, or operating a household appliance
• Confusion about time or place — losing track of dates, seasons, or the passage of time; forgetting where one is or how one got there
• Trouble with visual-spatial processing — difficulty judging distance, reading, or recognizing colors and contrast (beyond normal vision changes)
• New problems with words — struggling to follow or join a conversation, stopping mid-sentence without knowing how to continue, using incorrect words for familiar objects
• Misplacing things and losing the ability to retrace steps — placing items in unusual locations and being unable to reconstruct where they went
• Decreased or poor judgment — making uncharacteristic financial decisions, neglecting personal hygiene, or falling for scams
• Withdrawal from social or occupational activities — pulling back from hobbies, work projects, or social engagements
• Changes in mood and personality — increased anxiety, irritability, suspiciousness, depression, or apathy

As the disease progresses to the moderate stage, individuals typically need increasing assistance with daily activities such as dressing, bathing, and managing medications. Behavioral and psychological symptoms become more prominent, including agitation, wandering, sleep disturbances, delusions, and occasionally hallucinations.

In the severe stage, individuals lose the ability to communicate coherently, require full-time assistance with personal care, and eventually lose the ability to walk, sit, and swallow. Awareness of surroundings and recent experiences is profoundly diminished.

It is important to distinguish Alzheimer's-related cognitive decline from normal aging. Occasionally forgetting a name but recalling it later, misplacing keys once in a while, or taking slightly longer to learn new technology are common and generally benign age-related changes. In Alzheimer's disease, the changes are progressive, increasingly frequent, and increasingly disruptive to daily functioning.

The exact cause of Alzheimer's disease is not fully understood, but it is widely recognized as resulting from a complex interaction of genetic, biological, environmental, and lifestyle factors that develop over decades before symptoms appear.

Neuropathological mechanisms:

• Amyloid-beta plaques — Abnormal processing of amyloid precursor protein (APP) leads to the accumulation of amyloid-beta peptides that aggregate into plaques between neurons. These plaques disrupt cell-to-cell communication and trigger inflammatory responses.
• Neurofibrillary tangles — Hyperphosphorylated tau protein forms insoluble tangles inside neurons, disrupting the cell's internal transport system and ultimately leading to cell death.
• Neuroinflammation and synaptic loss — Chronic activation of microglia (the brain's immune cells) contributes to neuronal damage. Synaptic loss — the destruction of connections between neurons — is the pathological feature most closely correlated with cognitive decline.

Non-modifiable risk factors:

• Age — The single strongest risk factor. Risk increases substantially after age 65.
• Genetics — The APOE ε4 allele is the most significant genetic risk factor for late-onset Alzheimer's. Carrying one copy increases risk roughly 3-fold; carrying two copies increases risk approximately 8–12-fold. However, many APOE ε4 carriers never develop Alzheimer's, and many people who develop the disease do not carry this allele.
• Family history — Having a first-degree relative with Alzheimer's increases risk, reflecting both shared genetics and shared environmental exposures.
• Early-onset familial Alzheimer's — Rare autosomal dominant mutations in the APP, PSEN1, and PSEN2 genes cause early-onset forms (typically before age 65), accounting for fewer than 5% of all Alzheimer's cases.
• Down syndrome — Individuals with trisomy 21 carry an extra copy of the APP gene and have a substantially elevated risk of developing Alzheimer's-related pathology, often by their 40s or 50s.
• Sex — Women are disproportionately affected, making up nearly two-thirds of Alzheimer's cases. This difference is not fully explained by longer life expectancy and is an active area of research, with hormonal, genetic, and immune factors under investigation.

Modifiable risk factors:

A landmark report from The Lancet Commission on Dementia Prevention, Intervention, and Care (2020) identified 12 modifiable risk factors that collectively account for an estimated 40% of dementia cases worldwide:

• Less education (early life)
• Hearing loss, traumatic brain injury, hypertension, excessive alcohol consumption, obesity (midlife)
• Smoking, depression, social isolation, physical inactivity, air pollution, diabetes (later life)

This means that while Alzheimer's disease cannot be entirely prevented, population-level risk reduction is possible through public health interventions targeting cardiovascular health, educational access, social engagement, and hearing care.

Diagnosing Neurocognitive Disorder Due to Alzheimer's Disease involves a multi-step clinical process. There is no single test that confirms the diagnosis with certainty during a person's lifetime, though advances in biomarker testing have significantly improved diagnostic accuracy.

DSM-5-TR diagnostic criteria require the following:

• The individual meets criteria for either major or mild neurocognitive disorder — meaning there is evidence of significant (major) or modest (mild) cognitive decline from a previous level of performance in one or more cognitive domains (learning and memory, language, executive function, complex attention, perceptual-motor, or social cognition), based on both the individual's or an informant's concern and objective cognitive testing.
• The onset is insidious and progression is gradual.
• For major neurocognitive disorder: criteria are met for either "probable" or "possible" Alzheimer's. Probable is diagnosed if there is evidence of a causative genetic mutation (from genetic testing or family history) or if all three of the following are present: clear evidence of decline in memory and learning plus at least one other cognitive domain, steadily progressive decline without extended plateaus, and no evidence of mixed etiology.
• For mild neurocognitive disorder: probable is diagnosed if a causative genetic mutation is identified; otherwise, the diagnosis is possible.
• The disturbance is not better explained by cerebrovascular disease, another neurodegenerative disease, the effects of a substance, or another mental, neurological, or systemic disorder.

The diagnostic workup typically includes:

• Comprehensive clinical interview — Detailed history from the patient and a knowledgeable informant (family member, close friend) about the nature, onset, and progression of cognitive changes and their impact on daily functioning.
• Neuropsychological testing — Standardized cognitive assessments (e.g., the Montreal Cognitive Assessment [MoCA], neuropsychological test batteries) that objectively measure performance across cognitive domains and compare results to age- and education-adjusted norms.
• Neurological examination — Assessment of motor function, reflexes, cranial nerves, and gait to identify signs suggesting alternative or co-occurring neurological conditions.
• Laboratory testing — Blood work to rule out potentially reversible causes of cognitive decline, including thyroid dysfunction, vitamin B12 deficiency, electrolyte imbalances, liver or kidney disease, and syphilis.
• Structural neuroimaging — MRI (preferred) or CT of the brain to assess for hippocampal and cortical atrophy patterns consistent with Alzheimer's, and to rule out structural causes such as tumors, subdural hematomas, or normal pressure hydrocephalus.
• Biomarker testing (increasingly available) — Cerebrospinal fluid (CSF) analysis can detect low amyloid-beta 42 levels and elevated phosphorylated tau, consistent with Alzheimer's pathology. Amyloid PET imaging and tau PET imaging can visualize amyloid plaques and tau tangles in the living brain. Emerging blood-based biomarkers (plasma p-tau217, p-tau181, amyloid-beta ratios) are showing promising accuracy and may transform early detection.

It is critical to note that a definitive, "certain" diagnosis of Alzheimer's disease historically required neuropathological confirmation at autopsy. However, the combination of clinical evaluation and modern biomarker technology now allows clinicians to diagnose Alzheimer's with high confidence during life.

There is currently no cure for Alzheimer's disease. Treatment focuses on slowing disease progression, managing symptoms, supporting function, and improving quality of life for both the individual and their caregivers. The treatment landscape has evolved significantly in recent years.

Pharmacological treatments:

• Cholinesterase inhibitors — Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) are FDA-approved for mild to moderate Alzheimer's (donepezil is also approved for severe Alzheimer's). These medications work by inhibiting the breakdown of acetylcholine, a neurotransmitter important for memory and learning that is depleted in Alzheimer's disease. They provide modest symptomatic benefit — they do not halt disease progression but can stabilize or temporarily improve cognition and daily functioning for months to years in some individuals.
• NMDA receptor antagonist — Memantine (Namenda) is approved for moderate to severe Alzheimer's. It regulates glutamate activity, which when excessive can damage neurons. Memantine is often used in combination with a cholinesterase inhibitor.
• Anti-amyloid monoclonal antibodies — This represents a new class of disease-modifying treatments. Lecanemab (Leqembi), approved by the FDA in 2023, targets and clears amyloid-beta protofibrils from the brain. Clinical trials demonstrated a statistically significant slowing of cognitive and functional decline (approximately 27% slowing over 18 months compared to placebo) in individuals with early-stage Alzheimer's. Donanemab (Kisunla), approved in 2024, showed similar disease-modifying effects. These therapies require confirmation of amyloid pathology via PET scan or CSF testing before initiation and carry a risk of amyloid-related imaging abnormalities (ARIA) — brain swelling or microbleeds — requiring regular MRI monitoring.
• Medications for behavioral symptoms — Antidepressants (particularly SSRIs like sertraline or citalopram) may address depression and anxiety. Atypical antipsychotics (such as risperidone or quetiapine) are sometimes used cautiously for severe agitation, aggression, or psychosis, but they carry significant risks in older adults with dementia, including increased risk of stroke and mortality, and should be used only when non-pharmacological approaches have been insufficient and the symptoms pose a safety risk. Brexpiprazole (Rexulti) received FDA approval specifically for agitation associated with Alzheimer's dementia in 2023.

Non-pharmacological interventions:

Non-pharmacological approaches are considered first-line treatment for behavioral and psychological symptoms and are important throughout the disease course:

• Cognitive stimulation therapy (CST) — Structured group-based programs involving themed activities and discussions have demonstrated benefits for cognition and quality of life in mild to moderate dementia, with evidence comparable to cholinesterase inhibitors for cognitive outcomes.
• Physical exercise — Regular aerobic exercise (such as walking, swimming, or adapted exercise programs) has been associated with slower cognitive decline, improved mood, better sleep, and reduced behavioral symptoms.
• Occupational therapy — Helps individuals maintain independence in daily activities for as long as possible through environmental modifications, adaptive strategies, and caregiver training.
• Music therapy and art therapy — Research supports these approaches for reducing agitation, improving mood, and enhancing social engagement, even in moderate to severe stages.
• Behavioral management strategies — Identifying triggers for agitation or distress, maintaining consistent routines, simplifying communication, and creating a calm and structured environment can significantly reduce behavioral symptoms.
• Caregiver education and support — Caregiver interventions — including psychoeducation, skills training, respite care, and support groups — are an essential component of Alzheimer's treatment. Research consistently shows that caregiver well-being directly affects patient outcomes, and that structured caregiver programs can delay nursing home placement.

Alzheimer's disease is a progressive and ultimately terminal neurodegenerative condition. Unlike many psychiatric disorders, the trajectory does not involve recovery. However, the rate of progression varies considerably between individuals, and meaningful quality of life can be maintained — especially in earlier stages — with appropriate support and treatment.

Key facts about disease course:

• The average duration from diagnosis of Alzheimer's dementia to death is approximately 4–8 years, though some individuals live 10–20 years after diagnosis. Younger age at onset is associated with a longer disease course but often more aggressive cognitive decline.
• Progression through mild, moderate, and severe stages is gradual but relentless. Some individuals experience relatively slow decline for extended periods, while others deteriorate more rapidly.
• In the terminal stage, individuals are typically bedridden, nonverbal, and fully dependent on caregivers. Death most commonly results from complications such as aspiration pneumonia, infections, or malnutrition.
• Early diagnosis matters. While it cannot change the ultimate trajectory, earlier identification allows individuals to participate in treatment decisions, advance care planning, clinical trials, and legal and financial planning while they still have the capacity to do so.
• The emergence of disease-modifying therapies (anti-amyloid antibodies) represents a significant shift. While current agents offer modest slowing of decline rather than halting or reversing it, they establish the principle that the biological course of Alzheimer's can be altered, with the expectation that future combination therapies may yield greater benefit.

Families should be aware that anticipatory grief — mourning the gradual loss of a loved one's personality, memories, and abilities while they are still alive — is an extremely common and painful experience in Alzheimer's caregiving. Mental health support for caregivers is not a luxury; it is a clinical necessity.

Alzheimer's disease exists within a broader landscape of neurocognitive disorders and related conditions. Understanding these distinctions is important because different causes of cognitive decline may require different treatments and have different prognoses.

• Vascular Neurocognitive Disorder — The second most common cause of dementia, resulting from cerebrovascular disease (strokes, small vessel disease). Onset is often more abrupt, and progression may be stepwise rather than gradual. Many individuals have mixed Alzheimer's and vascular pathology.
• Neurocognitive Disorder with Lewy Bodies — Characterized by fluctuating cognition, visual hallucinations, REM sleep behavior disorder, and parkinsonism (slowness, rigidity, tremor). Shares pathological features with both Alzheimer's and Parkinson's disease.
• Frontotemporal Neurocognitive Disorder — A group of dementias caused by degeneration of the frontal and temporal lobes, often presenting with prominent changes in personality, behavior, or language rather than memory loss. Tends to occur at a younger age than Alzheimer's (often 45–65).
• Neurocognitive Disorder Due to Parkinson's Disease — Cognitive decline that develops in the context of established Parkinson's disease, typically appearing a year or more after motor symptoms.
• Mild Cognitive Impairment (MCI) — While not synonymous with early Alzheimer's, MCI represents a stage of cognitive decline beyond normal aging that does not yet meet criteria for major neurocognitive disorder. Not all individuals with MCI progress to Alzheimer's — some remain stable, and some revert to normal cognition.
• Delirium — An acute, fluctuating disturbance in attention and awareness, often caused by medical illness, medication, or infection. Delirium is common in individuals with Alzheimer's and can temporarily worsen cognitive functioning dramatically. It is a medical emergency requiring prompt identification and treatment of the underlying cause.
• Major Depressive Disorder — Depression can cause cognitive symptoms that mimic dementia (sometimes called "pseudodementia"), particularly in older adults. Depression is also a common comorbidity in Alzheimer's disease, affecting an estimated 20–40% of individuals with the condition.

Knowing when to seek evaluation is one of the most important steps in the Alzheimer's disease journey. Many families delay seeking help due to fear, denial, or the assumption that cognitive changes are a normal part of aging. Early evaluation is strongly recommended — not to cause alarm, but because early identification opens doors to treatment, planning, and support.

Seek professional evaluation if you or a loved one experience:

• Memory problems that are progressively worsening over weeks to months, particularly difficulty remembering recent events or conversations
• Increasing difficulty with tasks that were previously routine, such as managing finances, navigating familiar routes, or following multi-step instructions
• Noticeable changes in language abilities — frequently searching for words, losing the thread of conversations, or substituting incorrect words
• Confusion about time, place, or familiar people that cannot be explained by fatigue, medication, or a temporary medical condition
• Personality or behavioral changes — increased suspiciousness, apathy, irritability, social withdrawal, or uncharacteristic poor judgment
• Family members or friends expressing concern about cognitive changes — informant observations are often more reliable than self-report in the early stages of dementia

Where to start:

• A primary care physician can conduct an initial cognitive screening, order blood work and neuroimaging, and provide referrals.
• A neurologist specializes in the diagnosis and management of neurodegenerative conditions.
• A neuropsychologist can conduct detailed cognitive testing to characterize the pattern and severity of impairment.
• Geriatric psychiatrists specialize in the intersection of psychiatric symptoms and cognitive decline in older adults.
• Memory clinics and Alzheimer's disease research centers offer comprehensive, multidisciplinary evaluations and may provide access to clinical trials.

If a loved one with known Alzheimer's disease experiences a sudden or rapid worsening of cognition, new hallucinations, agitation, fever, or reduced consciousness, seek immediate medical attention — this may indicate delirium superimposed on dementia, a urinary tract infection, medication toxicity, or another treatable medical condition.

Remember: seeking evaluation is not about receiving a label — it is about gaining clarity, accessing support, and making informed decisions about the future. The Alzheimer's Association 24/7 Helpline (1-800-272-3900) provides immediate support, information, and referrals for anyone with questions or concerns.